论文部分内容阅读
不宁腿综合征为临床常见中枢神经系统感觉运动障碍性疾病,发病机制尚不明确,可能与遗传因素或多巴胺能系统功能失调有关。加巴喷丁恩那卡比最初由美国Xeno Port公司研发,之后由英国葛兰素史克公司通过并购获得,临床试验验证了其治疗不宁腿综合征的有效性。综述了加巴喷丁恩那卡比的研发背景、合成方法、药理学、药动学、临床评价、安全性和耐受性等研究进展,以期为临床上更好地应用提供依据。
Restless legs syndrome is a common clinical CNS sensory dyskinesia, the pathogenesis is not clear, and may be related to genetic factors or dopaminergic system dysfunction. Gabapentin Enkabi was originally developed by Xeno Port in the United States and was acquired by GlaxoSmithKline in the United States. Clinical trials validate its effectiveness in treating restless legs syndrome. This review summarizes the research progress of gabapentin nanakabi, its synthesis, pharmacology, pharmacokinetics, clinical evaluation, safety and tolerability, so as to provide a basis for better clinical application.